FATIREGUN AMINAT OMOLARA

Radiology

At the Radiology department office

Appointment on Visitation important

Topic: Prostate Cancer In Nigeria

Description: Prostate cancer is the 2nd commonest malignancy in men worldwide. It is, however, the most common in Nigeria. While several disparities have been documented between Caucasian men and men of African descent, there is limited research on prostate cancer in Nigeria. Evidence-based medicine is key in making clinical decisions and developing screening and treatment guidelines. This review assessed the levels of evidence on prostate cancer research in Nigeria. A systematic review of all research published on prostate cancer from January 1975 to May 2018 in Nigeria was conducted. We reviewed all articles on various databases by searching for Prostate cancer in Nigeria. We classified them based on their study designs into different levels of evidence and the year of publication. Meta-analyses were not considered in the review. A total of 171 articles were eligible for this review. Most publications were at the 4th 66% and 5th levels of evidence 17%, respectively. No clinical trials on prostate cancer in Nigeria were seen or registered on clinicaltrials.gov; hence, no studies at level 1a, b or c of evidence were published in Nigeria. The most common type of study design was cross-sectional studies, accounting for 56% of all publications. Prostate cancer research is currently at low levels of evidence in Nigeria. It is pertinent to explore and increase funding channels for cancer-related research.

#	Certificate	School	Year
1.	M.Sc (Clinical Oncology)	University of Birmingham, Birmingham, United Kingdom	2019

CLINICAL CHARACTERISTICS AND OUTCOMES OF POSITIVE COVID 19 CANCER PATIENTS IN LAGOS STATE.

Coronaviruses belong to the Coronaviridae family in the Nidovirales order. Corona represents crown-like spikes on the outer surface of the virus; thus, it was named as a coronavirus. On December 31, 2019, the China Health Authority alerted the World Health Organization WHO to several cases of pneumonia of unknown aetiology in Wuhan City in Hubei Province in central China. On January 7, a novel coronavirus, originally abbreviated as 2019-nCoV by WHO, was identified from the throat swab sample of a patient 2 . This pathogen was later renamed as severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 by the Coronavirus Study Group 3 and the disease was named corona virus disease 2019 COVID-19 by the WHO. WHO declared the SARS-CoV-2 outbreak as a Public Health Emergency of International Concern PHEIC 4 . In this pandemic, cancer patients are considered high risk as they are treated with a variety of immune system suppressor treatment modalities and this puts them in a great risk for infectious disease including COVID-19 . Furthermore, cancer patients may bear additional risk due to the restriction of access to the routine diagnostic and therapeutic services during such epidemic. According to a recently published Chinese cohort, patients with cancer had a higher risk of developing severe events intensive care unit admission, invasive ventilation, or death compared with patients without cancer 39 % vs 8%, p = 0 0003 5 . When Nigeria first reported its corona virus related death which occurred on March 22, 2020, the casualty was a cancer patient who had returned from the United Kingdom where he had gone for chemotherapy treatment 6 . This study aims to assess and document the prevalence, sociodemographic characteristics, COVID 19 signs and symptoms exhibited, and clinical outcome of Cancer patients who tested positive for the covid-19 virus in Nigeria.

FATIREGUN OMOLARA is a Lecturer I at the Department of Radiology

FATIREGUN has a M.Sc in Clinical Oncology from University of Birmingham, Birmingham, United Kingdom